Authors: Kline, T Fromhold, M McKennon, TE Cai, S Treiberg, J Ihle, N Sherman, D Schwan, W Hickey, MJ Warrener, P Witte, PR Brody, LL Goltry, L Barker, LM Anderson, SU Tanaka, SK Shawar, RM Nguyen, LY Langhorne, M Bigelow, A Embuscado, L Naeemi, E

Citation: T. Kline et al., Antimicrobial effects of novel siderophores linked to beta-lactam antibiotics, BIO MED CH, 8(1), 2000, pp. 73-93

Authors: MacLeod, DL Nelson, LE Shawar, RM Lin, BB Lockwood, LG Dirks, JE Miller, GH Burns, JL Garber, RL

Citation: Dl. Macleod et al., Aminoglycoside-resistance mechanisms for cystic fibrosis Pseudomonas aeruginosa isolates are unchanged by long-term, intermittent, inhaled tobramycintreatment, J INFEC DIS, 181(3), 2000, pp. 1180-1184

Authors: Shawar, RM MacLeod, DL Garber, RL Burns, JL Stapp, JR Clausen, CR Tanaka, SK

Citation: Rm. Shawar et al., Activities of tobramycin and six other antibiotics against Pseudomonas aeruginosa isolates from patients with cystic fibrosis, ANTIM AG CH, 43(12), 1999, pp. 2877-2880

Authors: Westbrock-Wadman, S Sherman, DR Hickey, MJ Coulter, SN Zhu, YQ Warrener, P Nguyen, LY Shawar, RM Folger, KR Stover, CK

Citation: S. Westbrock-wadman et al., Characterization of a Pseudomonas aeruginosa efflux pump contributing to aminoglycoside impermeability, ANTIM AG CH, 43(12), 1999, pp. 2975-2983

Authors: Burns, JL Van Dalfsen, JM Shawar, RM Otto, KL Garber, RL Quan, JM Montgomery, AB Albers, GM Ramsey, BW Smith, AL

Citation: Jl. Burns et al., Effect of chronic intermittent administration of inhaled tobramycin on respiratory microbial flora in patients with cystic fibrosis, J INFEC DIS, 179(5), 1999, pp. 1190-1196